Osborn Williams & Donohoe LLC Has $5.12 Million Position in Novartis AG (NYSE:NVS)

Osborn Williams & Donohoe LLC raised its position in shares of Novartis AG (NYSE:NVS) by 42.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 62,574 shares of the company’s stock after buying an additional 18,659 shares during the quarter. Osborn Williams & Donohoe LLC’s holdings in Novartis were worth $5,123,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of NVS. BlackRock Inc. increased its holdings in shares of Novartis by 223.5% during the fourth quarter. BlackRock Inc. now owns 11,439,298 shares of the company’s stock valued at $981,607,000 after acquiring an additional 7,902,964 shares in the last quarter. FMR LLC increased its holdings in Novartis by 441.6% in the 4th quarter. FMR LLC now owns 7,016,047 shares of the company’s stock worth $602,046,000 after buying an additional 5,720,650 shares in the last quarter. Bank of America Corp DE increased its holdings in Novartis by 25.1% in the 4th quarter. Bank of America Corp DE now owns 9,053,828 shares of the company’s stock worth $776,909,000 after buying an additional 1,817,005 shares in the last quarter. Mawer Investment Management Ltd. increased its holdings in Novartis by 53.4% in the 4th quarter. Mawer Investment Management Ltd. now owns 4,764,486 shares of the company’s stock worth $408,841,000 after buying an additional 1,658,037 shares in the last quarter. Finally, Boston Partners increased its holdings in Novartis by 26.1% in the 4th quarter. Boston Partners now owns 7,046,794 shares of the company’s stock worth $604,685,000 after buying an additional 1,459,845 shares in the last quarter. Hedge funds and other institutional investors own 11.82% of the company’s stock.

NYSE NVS traded up $3.08 during trading hours on Friday, reaching $87.52. The company’s stock had a trading volume of 4,711,326 shares, compared to its average volume of 2,540,707. The company has a current ratio of 0.93, a quick ratio of 0.83 and a debt-to-equity ratio of 0.48. Novartis AG has a 1 year low of $63.60 and a 1 year high of $85.08. The stock has a market cap of $195.06 billion, a PE ratio of 17.19, a P/E/G ratio of 1.98 and a beta of 0.66.

Novartis (NYSE:NVS) last released its quarterly earnings data on Wednesday, April 24th. The company reported $1.21 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.11 by $0.10. Novartis had a return on equity of 16.75% and a net margin of 24.55%. The business had revenue of $11.11 billion for the quarter, compared to the consensus estimate of $11.76 billion. During the same quarter in the previous year, the company posted $1.28 EPS. The company’s revenue was up 1.7% compared to the same quarter last year. On average, analysts forecast that Novartis AG will post 5 EPS for the current fiscal year.

Several research firms recently commented on NVS. Liberum Capital upgraded Novartis from a “hold” rating to a “buy” rating in a report on Thursday, April 25th. Zacks Investment Research downgraded Novartis from a “hold” rating to a “strong sell” rating in a research note on Thursday, April 11th. Guggenheim upgraded Novartis from a “neutral” rating to a “buy” rating and set a $79.16 price target for the company in a research note on Wednesday, April 24th. Morgan Stanley downgraded Novartis from an “equal weight” rating to an “underweight” rating and boosted their price target for the company from $82.50 to $82.52 in a research note on Wednesday, April 10th. Finally, JPMorgan Chase & Co. reaffirmed a “sell” rating on shares of Novartis in a research report on Tuesday, January 29th. Five analysts have rated the stock with a sell rating, four have given a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $87.57.

ILLEGAL ACTIVITY WARNING: This piece of content was posted by Sundance Herald and is owned by of Sundance Herald. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark laws. The legal version of this piece of content can be read at https://sundanceherald.com/2019/05/24/osborn-williams-donohoe-llc-has-5-12-million-holdings-in-novartis-ag-nvs.html.

Novartis Profile

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardio-metabolic, and established medicine products.

Read More: Net Margin – Understanding the Different Kinds of Profit

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply